Risankizumab Safe and Effective for Patients With Moderate to Severe Plaque Psoriasis Throughout a 52-Week Period

Risankizumab is a safe and effective treatment in different subgroups of patients with moderate to severe plaque psoriasis when treated for 52 weeks, regardless of body mass index status and presence of cardiometabolic comorbidities, according to a study published in Dermatology and Therapy.

Researchers aimed to assess the real-life effectiveness and safety of risankizumab in 131 patients with moderate to severe plaque psoriasis in a 52-week retrospective study. Patient characteristics and Psoriasis Area and Severity Index (PASI) score were recorded at each visit during the 52-week period. Patients achieving PASI 75/90/100 with respect to baseline were registered as percentages.

At week 52, 93.9% of patients achieved PASI 75, 78.6% achieved PASI 90, and 61.1% achieved PASI 100. Comparable percentages of patients achieved PASI 100 regardless of difficult-to-treat areas. Higher body mass index and cardiometabolic comorbidities did not interfere with reaching PASI 75/90/100 at each time point. A favorable safety profile was recorded with satisfactory tolerability.

“Our study confirmed the effectiveness of risankizumab throughout a 52-week period, with higher therapeutic responses at week 28, 40, and 52 compared to week 16,” concluded the study authors. “Our data demonstrate the high effectiveness of risankizumab in daily clinical practice in a large cohort of patients with moderate to severe plaque psoriasis, with the largest cohort of patients completing a full year of treatment,” they added.

Reference
Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309-2324. doi:10.1007/s13555-022-00795-x